Quoin Pharmaceuticals Ltd Stock In The News

QNRX Stock  USD 0.29  0.01  4.97%   
Our overall analysis of Quoin Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Quoin Pharmaceuticals Ltd. The specific impact of Quoin Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Quoin Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Quoin Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Quoin Pharmaceuticals Backtesting and Quoin Pharmaceuticals Hype Analysis.

Quoin Pharmaceuticals Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
https://www.globenewswire.com/news-release/2025/02/27/3033744/0/en/Quoin-Pharmaceuticals-Announces-Highly-Positive-Whole-Body-Clinical-Data-from-Ongoing-Pediatric-Netherton-Syndrome-Study.html
 Neutral
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
https://www.globenewswire.com/news-release/2025/02/25/3031904/0/en/Quoin-Pharmaceuticals-Launches-First-Episode-of-NETHERTON-NOW-Video-Series-to-Raise-Awareness-for-Netherton-Syndrome.html
 Neutral
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Launches ‘NETHERTO...
https://www.globenewswire.com/news-release/2025/02/04/3020192/0/en/Quoin-Pharmaceuticals-Launches-NETHERTON-NOW-Campaign-to-Raise-Awareness-of-Netherton-Syndrome-a-Rare-Genetic-Disease-with-No-Approved-Treatment-or-Cure.html
 Bullish
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/08/2776844/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Announces-Third-Quarter-2023-Financial-Results.html
 Bullish
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Announces Third Qu...
https://www.globenewswire.com/news-release/2023/11/03/2773195/0/en/Quoin-Pharmaceuticals-Announces-Third-Quarter-2023-Financial-Results-and-Corporate-Update-Conference-Call-to-be-held-on-Thursday-November-9th-at-8-30-am-ET.html
 Bullish
Macroaxis News: globenewswire.com
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
https://www.globenewswire.com/news-release/2023/10/24/2765741/0/en/REPEAT-Quoin-Pharmaceuticals-Announces-Additional-Positive-Clinical-Data-from-Open-Label-Single-Arm-Clinical-Trial-in-Netherton-Syndrome.html
 Bullish
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
https://www.globenewswire.com/news-release/2023/10/24/2765613/0/en/Quoin-Pharmaceuticals-Announces-Additional-Positive-Clinical-Data-from-Open-Label-Single-Arm-Clinical-Trial-in-Netherton-Syndrome.html
 Bullish
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/08/02/2717459/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Announces-Second-Quarter-2023-Financial-Results.html
 Bullish
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Announces Second Q...
https://www.globenewswire.com/news-release/2023/07/27/2712134/0/en/Quoin-Pharmaceuticals-Announces-Second-Quarter-2023-Financial-Results-and-Corporate-Update-Conference-Call-to-be-held-on-Thursday-August-3rd-at-8-30-am-ET.html
 Bullish
Macroaxis News: globenewswire.com
Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
https://www.globenewswire.com/news-release/2023/05/24/2675214/0/en/Quoin-Pharmaceuticals-Announces-50-Enrollment-in-Open-Label-Netherton-Syndrome-Clinical-Trial.html
 Neutral

Quoin Pharmaceuticals Ltd Past News Timeline

From Mar 25 to Dec 24Use up and down arrows to move selectionTo Mar 25Use up and down arrows to move upper selectionFrom Dec 24Use up and down arrows to move lower selectionUse TAB select grip buttons or up and down arrows to change selection100%
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Quoin and other traded companies coverage with news coverage. We help investors stay connected with Quoin headlines for the 25th of March to make an informed investment decision based on correlating the impacts of news items on Quoin Stock performance. Please note that trading solely based on the Quoin Pharmaceuticals Ltd hype is not for everyone as timely availability and quick action are needed to avoid losses.
Quoin Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Quoin Pharmaceuticals Ltd investors visualize upcoming and past events in order to time the market based on Quoin Pharmaceuticals Ltd noise-free hype analysis.
Quoin Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Quoin earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Quoin Pharmaceuticals that are available to investors today. That information is available publicly through Quoin media outlets and privately through word of mouth or via Quoin internal channels. However, regardless of the origin, that massive amount of Quoin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Quoin Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Quoin Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Quoin Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Quoin Pharmaceuticals alpha.

Quoin Largest EPS Surprises

Earnings surprises can significantly impact Quoin Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-05-08
2023-03-31-0.28-0.34-0.0621 
2025-03-11
2024-12-31-0.43-0.27810.151935 
2023-03-08
2022-12-31-0.62-0.410.2133 
2024-08-08
2024-06-30-0.61-0.390.2236 
2024-05-09
2024-03-31-0.76-1.11-0.3546 
2022-11-10
2022-09-30-1.35-0.940.4130 
View All Earnings Estimates

Quoin Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Quoin Pharmaceuticals Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
news
21st of March 2025
A Biotechnology and Bioengineering Design Award Unveils Comprehensive Prize Package for 20...
at kalkinemedia.com 
news
20th of March 2025
CBSE Biotechnology Exam Tomorrow, Check Important Questions Here
at ndtv.com 
businesswire News
19th of March 2025
MAIA Biotechnology Receives USAN Council Approval for Ateganosine as Nonproprietary Name f...
at businesswire.com 
Yahoo News
18th of March 2025
Human Augmentation Market to Grow USD 985.13 Billion by 2032, Driven by Advancements in AI...
at finance.yahoo.com 
Simply Wall St News at Macroaxis
14th of March 2025
Runben Biotechnology Is Reinvesting At Lower Rates Of Return
at simplywall.st 
news
12th of March 2025
Cizzle Biotechnology Hits New 1-Year Low Heres What Happened
at thelincolnianonline.com 
businesswire News
4th of March 2025
Asian Pharmaceutical Directory 2025 Top Source of Information on 10,000 Pharmaceutical and...
at businesswire.com 
Gurufocus Stories at Macroaxis
27th of February 2025
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
at gurufocus.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Quoin Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Quoin Pharmaceuticals' short interest history, or implied volatility extrapolated from Quoin Pharmaceuticals options trading.

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…